EUVIMEDEUVIMED entdecken
Multizentrische StudieVergleichsstudieOpen Access · CC BY 4.0

Comparison of effectiveness and safety of cefoperazone–sulbactam versus ceftriaxone and flomoxef in acute cholangitis: a multicenter retrospective study

Chieh-Chang Chen iD, Jiann-Hwa Chen, Wen-Hsin Huang, Tsung-Lin Hsieh, Li-Wei Chen, Ming-Chang Tsai, Nai-Jen Liu, Chi-Huan Wu, Chen-Shuan Chung, Yi-Chun Chiu, Chih-Ming Liang, Cheng-Kun Wu und 4 weitere

Antimicrobial Agents and Chemotherapy · 01.07.2026 · 70 (7)

DOI: 10.1128/aac.01829-25 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 01.07.2026. Verfasst von Chieh-Chang Chen und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan. Hauptthemen laut MEDLINE: Ceftriaxone, Cholangitis, Cefoperazone, Sulbactam. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acute cholangitis is a potentially life-threatening biliary tract infection requiring prompt antibiotic therapy. Cefoperazone–sulbactam is a recommended option for mild-to-moderate disease, but comparative evidence versus ceftriaxone and flomoxef is limited. In this multicenter retrospective study, 389 adults with acute cholangitis from nine Taiwanese centers (January 2022–July 2024) received cefoperazone–sulbactam ( n = 249), ceftriaxone ( n = 37), or flomoxef ( n = 103). The primary outcome was clinical response (cure or improvement) on days 4, 7, and 14. Secondary outcomes were microbiological response, in-hospital mortality, and adverse events (AEs). Multivariable logistic regression was performed, adjusting for age, sex, biliary stenting, comorbidities, malignancy, disease severity, and timing of biliary drainage. Baseline characteristics were similar across groups (mean age, 67 years; 91.8% had mild-to-moderate disease; 33.2% had bacteremia). Day 4 clinical response rates were 96.8% with cefoperazone–sulbactam, 97.3% with ceftriaxone, and 93.2% with flomoxef ( P = 0.05). Day 7 response did not differ significantly. Compared with cefoperazone–sulbactam, the adjusted odds ratio for day 4 clinical response was 1.40 (95% confidence interval [CI]: 0.17–11.78) for ceftriaxone and 0.50 (95% CI: 0.18–1.43) for flomoxef. AEs were uncommon (2%–5%), mostly mild and not associated with sequelae. Cefoperazone–sulbactam appears to be an effective and safe empiric therapy for acute cholangitis in real-world practice, with high observed early clinical response rates. Although outcomes were statistically similar to those of ceftriaxone and flomoxef, the underpowered between-group comparisons preclude definitive conclusions regarding comparative efficacy. These findings support its continued clinical use while awaiting confirmation in larger randomized trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CeftriaxoneCholangitisCefoperazoneSulbactamAnti-Bacterial AgentsCephalosporinsHumansRetrospective StudiesFemaleAgedMaleMiddle AgedThird Generation CephalosporinsSecond Generation CephalosporinsAcute DiseaseTreatment Outcome

Stichwörter der Autor:innen

acute cholangitisbiliary tract infectioncefoperazone–sulbactamceftriaxoneempirical antibioticsextended-spectrum β-lactamase (ESBL)flomoxef

Substanzen

CeftriaxoneCefoperazoneSulbactamAnti-Bacterial AgentsflomoxefCephalosporinsThird Generation CephalosporinsSecond Generation Cephalosporins

Autor:innen und Institutionen

  • Division of Gastroenterology and Hepatology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
  • Department of Internal Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan.
  • Division of Gastroenterology and Hepatology, Taipei Tzu Chi Hospital, New Taipei City, Taiwan.
  • School of Medicine, Tzu Chi University, Hualien, Taiwan.
  • Center for Digestive Medicine, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan.
  • Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital and Chang Gung University at Keelung, Keelung, Taiwan.

ORCID-Profile: Chieh-Chang Chen, Hsiu-Po Wang

Zitieren

APA

Chen, C. C., Chen, J., Huang, W. H., Hsieh, T. L., Chen, L. W., Tsai, M. C., Liu, N. J., Wu, C. H., Chung, C. S., Chiu, Y. C., Liang, C. M., Wu, C. K., Wang, W. L., Lee, C. T., Hsu, M. H., & Wang, H. P. (2026). Comparison of effectiveness and safety of cefoperazone–sulbactam versus ceftriaxone and flomoxef in acute cholangitis: a multicenter retrospective study. Antimicrobial Agents and Chemotherapy, 70(7). https://doi.org/10.1128/aac.01829-25

Vancouver

Chen CC, Chen J, Huang WH, Hsieh TL, Chen LW, Tsai MC, et al. Comparison of effectiveness and safety of cefoperazone–sulbactam versus ceftriaxone and flomoxef in acute cholangitis: a multicenter retrospective study. Antimicrobial Agents and Chemotherapy. 2026;70(7). doi:10.1128/aac.01829-25

BibTeX
@article{Chen2026,
  author = {Chen, Chieh-Chang and Chen, Jiann-Hwa and Huang, Wen-Hsin and Hsieh, Tsung-Lin and Chen, Li-Wei and Tsai, Ming-Chang and Liu, Nai-Jen and Wu, Chi-Huan and Chung, Chen-Shuan and Chiu, Yi-Chun and Liang, Chih-Ming and Wu, Cheng-Kun and Wang, Wen-Lun and Lee, Ching-Tai and Hsu, Ming-Hung and Wang, Hsiu-Po},
  title = {Comparison of effectiveness and safety of cefoperazone–sulbactam versus ceftriaxone and flomoxef in acute cholangitis: a multicenter retrospective study},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2026},
  volume = {70},
  number = {7},
  doi = {10.1128/aac.01829-25}
}
Kostenlos starten →